Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-07-04 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON GLOBAL MULTICENTER PHASE III STUDY OF NOFAZINLIMAB IN HEPATOCELLULAR CARCINOMA
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on CStone Pharmaceuticals’ latest clinical trial (Phase III) update, comprising forward-looking statements, study details, and regulatory disclaimers. It is not a financial report (10-K, IR, ER), not an AGM or dividend notice, nor a management change, proxy, or capital/financing update. This type of miscellaneous regulatory announcement falls under the general Regulatory Filings (RNS) category.
2025-07-04 English
Monthly Return
Regulatory Filings Classification · 1% confidence The document is a routine monthly submission (HKEX Form FF301) of movements in authorised/registered share capital, issued shares, and treasury shares, filed with Hong Kong Exchanges under Listing Rules Chapter 19B. It is not a financial report, earnings release, AGM material, capital raising announcement, or any other specific category. It is a regulatory return without a specific event, fitting the fallback category of Regulatory Filings (RNS).
2025-07-03 English
VOLUNTARY ANNOUNCEMENT - CSTONE UNVEILS TWO BISPECIFIC ANTIBODY TARGETS FOR AUTOIMMUNE/INFLAMMATORY DISEASES
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement under HKEX rules disclosing two internally developed bispecific antibody targets, with forward-looking statements, CEO commentary, and corporate background. It does not contain financial results, earnings figures, board changes, dividends, or any specialized report format. It is not a presentation deck, proxy material, or formal financial report. Therefore, it fits the fallback category for general regulatory announcements.
2025-07-03 English
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE
Governance Information Classification · 1% confidence The document is titled “Terms of Reference of the Nomination Committee” and outlines the composition, authority, duties, and procedures of a board sub-committee. It focuses on corporate governance structure and processes, rather than financial results, financing, legal proceedings, or event announcements. This aligns with the Governance Information category (CGR).
2025-06-25 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Governance Information Classification · 1% confidence The document provides a list of the company’s board members and their committee roles, detailing the board structure and governance arrangements. It does not announce changes in board composition, nor is it a proxy or remuneration report. This aligns with a Governance Information filing (Code: CGR).
2025-06-25 English
(1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025&#x3b; (2) RETIREMENT AND RESIGNATION OF DIRECTORS&#x3b; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an announcement of the Annual General Meeting poll results and details of resolutions passed (votes for and against), followed by notice of retirements and resignations of directors and changes in board committee composition. The primary focus at the top is on the poll results of the AGM, which falls squarely under Declaration of Voting Results & Voting Rights Announcements (DVA). Although it also announces director changes (MANG), the leading item and format identify it as a shareholder vote result notice. Hence, it should be classified as DVA.
2025-06-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.